Zydus Lifesciences Completes Merger of Assertio Holdings Inc.
Zydus Lifesciences Limited completed the merger of Zara Merger Sub Inc. into Assertio Holdings Inc., making Assertio a wholly-owned subsidiary. The transaction involved an offer price of USD 23.50 per share, totaling USD 166.33 million (approx. ₹1388 crore). Assertio's product ROLVEDON® had a turnover of USD 68.23 million (approx. ₹570 crore) in CY2025.
The acquisition of Assertio, a specialty oncology pharmaceutical company, is a significant strategic move that is expected to strengthen Zydus Lifesciences' position in the oncology market. The financial consideration involved is substantial, indicating a medium to high impact.
The completion of the merger and acquisition of Assertio Holdings Inc. as a wholly-owned subsidiary is a strategic positive development for Zydus Lifesciences, enhancing its oncology portfolio and market presence.
Zydus Lifesciences Limited has announced the completion of the merger of Zara Merger Sub Inc. with and into Assertio Holdings Inc. (Assertio). Following this merger, Assertio has now become a wholly-owned subsidiary of Zydus Lifesciences.
As a result of this transaction, the common stocks of Assertio are no longer listed or traded on the Nasdaq Global Market. The acquisition of all outstanding shares of Assertio's common stock has been consummated through this merger process.
Zara Merger Sub Inc., a step-down wholly-owned subsidiary of Zydus Lifesciences, was incorporated on April 24, 2026, specifically as an acquisition subsidiary. Assertio, a U.S.-based specialty oncology pharmaceutical company, has an established commercial capability for marketing and distributing differentiated oncology products. Its product, ROLVEDON® (eflapgrotim-xnst), approved by USFDA, is a long-acting G-CSF biologic used for preventing febrile neutropenia in adult cancer patients undergoing myelosuppressive chemotherapy. ROLVEDON® is administered once per chemotherapy cycle. The adjusted turnover for Assertio's product ROLVEDON® for the calendar year ended December 31, 2025, was USD 68.23 million (approximately ₹570 crore).
The rationale for the merger was to acquire outstanding shares and control over Assertio, thereby making it a wholly-owned subsidiary. The offer price was USD 23.50 per share in cash, representing a total consideration of USD 166.33 million (approximately ₹1388 crore) on a fully diluted basis. This includes the consideration for common stock not tendered into the offer that has the right to receive cash equal to the offer price.
What to do with a filing like this
Zydus Lifesciences Limited filed this with the NSE as a statutory disclosure, categorised under merger. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Zydus Lifesciences Limited. Read the original for the full detail.